FET-PET for Diagnosis and Monitoring in Patients With Low Grade Glioma
This trial is active, not recruiting.
|Conditions||astrocytoma, oligoastrocytoma, oligodendroglioma|
|Sponsor||Ludwig-Maximilians - University of Munich|
|Collaborator||Deutsche Krebshilfe e.V., Bonn (Germany)|
|Start date||June 2008|
|End date||December 2015|
|Trial size||38 participants|
|Trial identifier||NCT01089244, GGN-CP4|
The aim of the study is to compare the two imaging modalities perfusion weighted MR-imaging and FET-PET in their ability to provide an accurate histological evaluation of low grade glioma and to reveal focal abnormalities within a homogeneously appearing tumor. Additionally, therapeutic effects should be assessed during a time period of two years.
|United States||No locations recruiting|
|Other countries||No locations recruiting|
Patients with a suspected WHO II low grade glioma, disease progression within 1 year
Patients with a suspected WHO II low grade glioma, progression free within 1 year
time frame: 24 months
Progression Free survival
time frame: 24 months
Male or female participants at least 18 years old.
- neuroradiologically suspected low grade glioma (Astrocytoma WHOI-II, Oligodendroglioma WHO II, Oligoastrocytoma WHO II)
- histological verification will be obtained either by microsurgery or by stereotactic biopsy
- patients older than 18 years
- Karnofsky Performance Score >=70
- pregnant or nursing female patients will not be included in this study
- patients in whom informed consent cannot be obtained due to organic brain syndrome or insufficient language skills
- patients who cannot lie quiet for a time period of app. two hours during the FET-PEt scan
- medical history of a metastatic brain disease
- patients in whom an MRI scan cannot be performed due to claustrophobia metallic protheses or pacemakers etc.
|Official title||Molecular Correlates and Clinical Significance of Positron Emission Tomography With FET-PET in Combination With Perfusion-weighted Magnetic Resonance Imaging (PWI) in Patients With Low Grade Gliomas|
|Principal investigator||Joerg C. Tonn, Prof. Dr.|
Call for more information